English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 12 October 2022, 13:00 HKT/SGT

Source: Malaysian Genomics Resource Centre Bhd
Malaysian Genomics Signs Agreement with National Institutes of Health to Explore Research Opportunities
Both parties to collaborate on research in genomics and biopharmaceuticals

PETALING JAYA, Malaysia, Oct 12, 2022 - (ACN Newswire) - MGRC Therapeutics Sdn Bhd (MGRC-T), a wholly-owned subsidiary of Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, has entered into a cooperation agreement with the National Institutes of Health, Malaysia (NIH), providing a framework for collaboration between the two parties in medical research pertaining to genomics and biopharmaceuticals.

Dato' Alvin Joseph Nesakumar, Executive Director of Malaysian Genomics

The National Institutes of Health (NIH), the research arm under the Ministry of Health Malaysia, comprises six research institutes that focus on biomedical research, public health and epidemiology, clinical research, behavioural health research, health management and health policies. The NIH is mandated to conduct high-impact health research to improve the quality of life of the Rakyat. The health research conducted by the NIH is in line with the Health Research Priority Areas for each five-yearly Malaysia Plans.

MGRC-T specialises in genomics and biopharmaceutical services with proprietary know-how and intellectual property related to the research, development, and processing of genetic screening tests, as well as the manufacturing of cell therapies, including immunotherapy for various types of cancer.

Dato' Alvin Joseph Nesakumar, Executive Director of Malaysian Genomics, said, "The cooperation agreement enables us to explore ways that we can work together with NIH to improve the quality of our genomics and biopharmaceutical services that can contribute to improving the health of the Rakyat. We consider this collaboration a good step in encouraging and promoting research in genomics and biopharmaceuticals that will be mutually beneficial."

Dr S Asmaliza Ismail, Manager of the NIH said, "We welcome this agreement as we are keen to work with specialists such as Malaysian Genomics to exchange knowledge in various fields of medical research. We believe that by working and pooling our resources together, we can bridge the gaps in expertise and experience."

Under this agreement, the parties will explore joint training in the field of medical research, exchange research materials, and partake in scientific data presentation and publication. Additionally, the agreement will enable the exchange of experts and personnel, including postgraduate research and students on adjunct appointments, short- and long-term research attachments, co-supervision of students conducting research and internships, as well as other areas of cooperation to be mutually decided.

Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/

Topic: Press release summary
Source: Malaysian Genomics Resource Centre Bhd

Sectors: Daily Finance, BioTech, Healthcare & Pharm
From the Asia Corporate News Network

Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Malaysian Genomics Resource Centre Bhd Related News
Aug 29, 2023 13:00 HKT/SGT
Malaysian Genomics Unveils Strategic Advances in Biopharmaceuticals
May 15, 2023 18:00 HKT/SGT
Malaysian Genomics Inks Agreement in Expansion to Bangladesh
Feb 27, 2023 13:00 HKT/SGT
Malaysian Genomics to Boost Play on the Football Pitch
Feb 24, 2023 17:30 HKT/SGT
Malaysian Genomics Pivots to Biopharmaceuticals for Growth
Feb 24, 2023 13:30 HKT/SGT
Malaysian Genomics to Collaborate on Cannabinoid R&D
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575